Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Truqap approved in US for HR+ breast cancer

17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhibitor has potential to reshape…

AstraZenecas (AZN) Capivasertib Gets FDA Nod for Breast Cancer

AstraZenecas (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.…

Pharma Stock Roundup: FDA Okays AZNs Capivasertib & MRKs Keytruda Expanded Use

FDA approves AstraZenecas (AZN) new breast cancer drug, Truqap, and the expanded use of Mercks (MRK) Keytruda in a gastric…

Cellectis stock jumps on execution of $140M additional investment with AstraZeneca

…

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that,…

AstraZenecas (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AstraZenecas (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.…

Astrazeneca: Wichtiges Medikament erreicht Ziel in Lungenkrebsstudie nicht

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem seiner Kassenschlager erlitten. Eine…

Kaum Impulse für die AstraZeneca-Aktie (59,2271 €)

Im Wertpapierhandel ist der Anteilsschein von AstraZeneca zur Stunde unauffällig. Die Aktie notiert derzeit bei 63,37 US-Dollar. Der heutige Börsentag…

AstraZeneca: Jahresziele erhöht - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

…

AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead

"The incumbent almost always wins," Jim Cramer said this week.…

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral…

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.…

AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript

AZN earnings call for the period ending September 30, 2023.…

AstraZeneca PLC 2023 Q3 - Results - Earnings Call Presentation

…

AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript

…

Theres a new entry into the weight loss drug boom. Heres the outlook for the stock

AstraZeneca is the latest player to enter the weight loss drug market, which analysts predict could reach $100 billion by…

AstraZeneca CFO: Obesity Market Has a Lot of Potential

AstraZeneca CFO Aradhana Sarin discusses the companys third-quarter results and its plans to develop an obesity pill. The treatment developed…

FTSE 100 helped higher by AstraZeneca and Taylor Wimpey

The FTSE 100 gained on Thursday as macroeconomic concerns took a back seat and investors focused on corporate earnings. Upbeat…

Director Declaration

9 November 2023 15:00 BST Director Declaration AstraZeneca PLC (the Company) today announced that Philip Broadley,senior independent Non-Executive Directorof the Company, has…

AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows

The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.…

AstraZeneca: "Take some reassurance” from obesity drug bet

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide…

AstraZeneca could "take some reassurance” from obesity drug bet

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year in the hope that its foray into a semaglutide…

ROUNDUP: Astrazeneca stemmt sich gegen Umsatzschwund im Covid-Geschäft

CAMBRIDGE (dpa-AFX) - Astrazeneca hat den Umsatzschwund bei Covid-Arzneien auch im dritten Quartal gut verkraftet. Der britisch-schwedische Pharmakonzern profitierte…

Movers & Shakers: Virgin Galactic shares surge as space firm doubles revenue while Walt Disney stock jumps on spike in streaming customers

Shares in Virgin Galactic, Bill Holdings, Walt Disney Co, AstraZeneca, Topgolf Callaway, Allbirds, Bill Holdings, and Lyft shares were all…

AstraZeneca lifts forecast after strong Q3, signs $2B deal for obesity drug

…

: AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines

AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate…

AstraZeneca lifts full-year guidance for EPS, revenue despite profit miss

AstraZeneca lifts full-year guidance for EPS, revenue despite profit miss…

AstraZeneca reports mixed Q3 earnings; raises FY23 outlook

…

AstraZeneca Raises Outlook, Clinches Obesity Drug Deal

AstraZeneca Plc raised its profit outlook for the year and clinched a deal to develop a drug from the pharma…

Imfinzi combination improves PFS in liver cancer

09 November 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III…

AstraZeneca hikes annual profit outlook By Reuters

AstraZeneca hikes annual profit outlook…

Agreement with Eccogene for clinical stage GLP-1RA

09 November 2023 AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Global rights to Eccogenes next-generation oral glucagon-like…

9M and Q3 2023 results

AstraZeneca 9 November 2023 9M and Q3 2023 results Strong momentum in the year to date leads to increased guidance for Total Revenue…

AstraZeneca reports, Li Auto earnings, Tapestry: 3 things to watch By Investing.com

AstraZeneca reports, Li Auto earnings, Tapestry: 3 things to watch…

AstraZeneca: Revenue Softening Possible, Profits To Rise

…

Tagesvorschau: Termine am 09. November 2023

Viele Unternehmen, unter anderem Merck KGaA, Sony, Astrazeneca, legen heute ihre Zahlen vor. Außerdem stehen wichtige Wirtschaftsdaten aus China, Japan…

US FTC disputes listing for more than 100 patents in FDA Orange Book

The U.S. Federal Trade Commission (FTC) on Tuesday said it sent notice letters to Abbvie , AstraZeneca , Teva and…

DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Hold

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Hold" mit einem Kursziel von 11000 Pence…

Asia Cervical Cancer Screening Markets, 2023-2028 with AstraZeneca, Hologic, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health Dominating

Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends,…

AstraZeneca (AZN) to Report Q3 Earnings: Whats in the Cards?

Higher sales of AstraZenecas (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the…

Total Voting Rights

1 November 2023 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

: Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based…

dpa-AFX ProFeed